Evidence map›Paper›PMID 31969476›Full record

ArticlemSphere2020

Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1.

Heather Friberg, Luis J Martinez, Leyi Lin, Jason M Blaylock, Rafael A De La Barrera, Alan L Rothman, J Robert Putnak, Kenneth H Eckels, Stephen J Thomas, Richard G Jarman and 1 more

Open access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in mSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Heather FribergViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA heather.l.friberg-robertson.civ@mail.mil.ORCID 0000-0001-5173-2701
Luis J MartinezViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Leyi LinViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Jason M BlaylockViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Rafael A De La BarreraPilot Bioproduction Facility, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Alan L RothmanInstitute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island, USA.
J Robert PutnakViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Kenneth H EckelsPilot Bioproduction Facility, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Stephen J ThomasViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Richard G JarmanViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Jeffrey R CurrierViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Walter Reed Army Institute of Research · USUniversity of Rhode Island · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dengue is the most prevalent arboviral disease afflicting humans, and a vaccine appears to be the most rational means of control. Dengue vaccine development is in a critical phase, with the first vaccine licensed in some countries where dengue is endemic but demonstrating insufficient efficacy in immunologically naive populations. Since virus-neutralizing antibodies do not invariably correlate with vaccine efficacy, other markers that may predict protection, including cell-mediated immunity, are urgently needed. Previously, the Walter Reed Army Institute of Research developed a monovalent purified inactivated virus (PIV) vaccine candidate against dengue virus serotype 1 (DENV-1) adjuvanted with alum. The PIV vaccine was safe and immunogenic in a phase I dose escalation trial in healthy, flavivirus-naive adults in the United States. From that trial, peripheral blood mononuclear cells obtained at various time points pre- and postvaccination were used to measure DENV-1-specific T cell responses. After vaccination, a predominant CD4

Indexed as

Immunity, CellularAdultCD4-Positive T-LymphocytesCell ProliferationCytokinesDengueDengue VaccinesDengue VirusFemaleHumansInterferon-gammaInterleukin-2Leukocytes, MononuclearMaleMiddle AgedPeptidesCytokinesDengue VaccinesInterferon-gammaInterleukin-2PeptidesVaccines, InactivatedViral ProteinsCMIdenguePIVT cellsvaccine

Identifiers

PMID31969476
PMCPMC6977178
OpenAlexW3000847834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.